Citation Impact
Citing Papers
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
Ruxolitinib: A Review in Polycythaemia Vera
2015
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
2011
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
2017
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
The promise of Janus kinase inhibitors in the treatment of hematological malignancies
2016
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
2015
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
2020
Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study
2019
Works of Ryan McGee being referenced
The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
2011
The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers
2011